Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

European Journal of Cancer

Volumn 50, Issue 4, 2014, Pages 862-863

  Gonzalez Martin, Antonio ^a   Gladieff, Laurence ^b   Tholander, Bengt ^c   Stroyakovsky, Daniel ^d   Gore, Martin ^e   Scambia, Giovanni ^f   Oaknin, Ana ^g   Sneller, Vesna ^h   Freudensprung, Ulrich ^h   Pignata, Sandro ⁱ  

^a MD ANDERSON CANCER CENTER   (Spain)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Moscow Oncological Hospital No 62   (Russian Federation)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CATHOLIC UNIVERSITY   (Italy)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84894077171     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.12.001     Document Type: Letter

References (3)

1. A. Gonzalez-Martin, L. Gladieff, B. Tholander, D. Stroyakovsky, M. Gore, and G. Scambia et al. on behalf of the OCTAVIA Investigators. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer Eur J Cancer 49 18 2013 3831 3838
2. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen ICON7 Investigators A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
3. A.M. Oza, T.J. Perren, A.M. Swart, W. Schröder, E. Pujade-Lauraine, and H. Havsteen et al. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer Eur J Cancer 49 Suppl. 3 2013 S4 (abstract LBA6)